Specify a stock or a cryptocurrency in the search bar to get a summary
Sequana Medical NV
SEQUASequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, Switzerland, and internationally. The company products pipeline comprises alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid overload spread across the body and heart failure. Sequana Medical NV was founded in 2006 and is headquartered in Ghent, Belgium. Address: Kortrijksesteenweg 1112, Gent, Belgium, 9051
Analytics
WallStreet Target Price
3.98 EURP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures SEQUA
Dividend Analytics SEQUA
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History SEQUA
Stock Valuation SEQUA
Financials SEQUA
Results | 2019 | Dynamics |